Exuma Biotechnology

12 articles about Exuma Biotechnology

• EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit

  9/16/2022

  EXUMA Biotech, Corp. announced that pre-clinical data from its solid-tumor subcutaneous CAR therapy program will be presented at the virtual 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology hosted by the Center of Excellence in Immunology of the National Cancer Institute from September 15 - 16, 2022. 

• EXUMA Biotech to Participate in the Upcoming Baird Global Healthcare Investor Conference in September 2022

  9/8/2022

  EXUMA Biotech, Corp. announced that its Chief Business Officer and Head of Finance, Dr. Gregory Wade, will provide a corporate presentation at 11:25 AM ET on Wednesday, September 14, 2022, as part of the annual Baird Global Healthcare Conference in New York.

• EXUMA Biotech Announces Participation in the In Vivo Engineering of Therapeutic Cells Summit

  7/6/2022

  EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that Dr. Sid Kerkar , the company's Vice President of Oncology, Research and Development, will participate in the In Vivo Engineering of Therapeutic Cells Summit.

• 

  EXUMA’s CAR-TaNK Cells Could Eliminate Need for Preparative Chemotherapy

  4/12/2022

  EXUMA Biotech is developing a new modality to produce CAR cells in a single day, with potentially lower toxicity and higher efficacy without the need for preparative chemotherapies.

• EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting

  3/15/2022

  EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at the American Association for Cancer Research (AACR) Annual Meeting.

• EXUMA Biotech to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

  9/22/2021

  EXUMA Biotech, Corp. today announced that Chairman and Chief Executive Officer, Gregory Frost , Ph.D., will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021, from 2:40-3:10 p.m. ET.

• EXUMA Biotech Adds H. Michael Shepard to Scientific Advisory Board and Steven R. Frank to Board of Directors

  6/16/2020

  EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that H. Michael Shepard , Ph.D., an acting advisor to the company's HER2 program, has been appointed to the Scientific Advisory Board. Additional

• F1 Oncology to Present Data That Expands on Proof of Novel Point of Care Approach for CAR-T Therapies in Solid Tumor Malignancies

  3/31/2019

  Data Presented at 2019 AACR Annual Meeting Supports Novel Conditionally Active Biologics CAR-T Technology

• F1 Oncology's International Affiliate, EXUMA Biotechnology, Announces Acquisition Of Strategic CAR-T Assets

  11/13/2018

  F1 Oncology, Inc., today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a wholly foreign-owned enterprise (WFOE), to acquire all rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in Shanghai and Shenzhen

• F1 Oncology Announces Development Milestone and $10M Equity Investment

  1/8/2018

  The two conditionally active CAR-T cellular products targeting AXL and ROR2 will be tested in subjects with refractory, advanced stage mRCC.

• F1 Oncology's International Affiliates and Sinobioway Sunterra Biotech Announce New Development, Manufacturing, and Supply Agreements to Support cGMP Lentivirus Supply

  1/7/2018

  The new facility, Shenzhen Biowit, which will expand from the current clinical production staff and site in Shenzhen, is scheduled for completion in 2018 and will utilize F1 Oncology's chemically defined suspension-based lentivirus manufacturing technology and processes.

• BioAtla And F1 Oncology Announce Global Collaboration To Develop Adoptive Cellular Therapies For Solid Tumors

  1/6/2017